Pomalidomide-dexamethasone in refractory multiple myeloma: Long-term follow-up of a multi-cohort phase II clinical trial.

about

CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma

P2860

Q57801281-2B9C2CBA-24BD-4E94-B2E3-27E861B2BD8E

P2860

Pomalidomide-dexamethasone in refractory multiple myeloma: Long-term follow-up of a multi-cohort phase II clinical trial.

Item

http://www.wikidata.org/entity/Q38599023

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Pomalidomide-dexamethasone in ...... ohort phase II clinical trial.

@en

type

Item

label

Pomalidomide-dexamethasone in ...... ohort phase II clinical trial.

@en

prefLabel

Pomalidomide-dexamethasone in ...... ohort phase II clinical trial.

@en

P1476

Pomalidomide-dexamethasone in ...... ohort phase II clinical trial.

@en

P2093

A A Chanan-Khan

http://www.w3.org/2001/XMLSchema#string

A Dispenzieri

http://www.w3.org/2001/XMLSchema#string

A K Stewart

http://www.w3.org/2001/XMLSchema#string

B R LaPlant

http://www.w3.org/2001/XMLSchema#string

C B Reeder

http://www.w3.org/2001/XMLSchema#string

D Dingli

http://www.w3.org/2001/XMLSchema#string

F K Buadi

http://www.w3.org/2001/XMLSchema#string

J A Lust

http://www.w3.org/2001/XMLSchema#string

J R Mikhael

http://www.w3.org/2001/XMLSchema#string

K M Laumann

http://www.w3.org/2001/XMLSchema#string

P2860

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.

Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.

P2888

leu.2017.258

P31

scholarly article

P356

10.1038/LEU.2017.258

http://www.w3.org/2001/XMLSchema#string

P50

S. Vincent Rajkumar

Robert A Kyle

P577

2017-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1091414058

http://www.w3.org/2001/XMLSchema#string

P698

28860655

http://www.w3.org/2001/XMLSchema#string

P921

dexamethasone

phase II clinical trial

Pomalidomide-dexamethasone in refractory multiple myeloma: Long-term follow-up of a multi-cohort phase II clinical trial.

about

P2860

P2860

Pomalidomide-dexamethasone in refractory multiple myeloma: Long-term follow-up of a multi-cohort phase II clinical trial.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P31

P356

P50

P577

P6179

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P31

P356

P50

P577

P6179

P698

P921